Immunic Late-stage Program for Lead Asset to Proceed as Planned
Immunic Phase 3 MS Study Advances Following Positive Recommendation From Independent Committee | NASDAQ:IMUX
GRI Bio GRI Warrants Exercised; Immunic IMUX Phase 3 IDMC Recommendation
Immunic Shares Advance on Positive Outcome From Interim Analysis of Potential MS Treatment
EF Hutton Maintains Buy on Immunic, Maintains $17 Price Target
Immunic Analyst Ratings
Express News | Immunic Shares up 23.2% Premarket After Co Reports Interim Late-Stage Study Data for Experimental Multiple Sclerosis Drug
Express News | Immunic: Idmc Recommended Continuing Trial Without Changes, Including No Need for Potential Upsizing
Express News | Immunic Inc: Ensure Program Remains on Track to Be Completed in 2026
Express News | Eqs-News: Immunic Announces Positive Outcome of Interim Analysis of Phase 3 Ensure Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis
Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis
Immunic Stock's Popularity Rises With Consistent Buy Ratings From Analysts
Brookline Capital Maintains Immunic(IMUX.US) With Buy Rating, Raises Target Price to $13
Top Premarket Gainers
Immunic Inc (IMUX) Q2 2024 Earnings Call Highlights: Promising Clinical Data and Financial ...
B. Riley Reacts to Immunic's Update on Clinical Benefits of Vidofludimus Calcium
Analysts Are Bullish on Top Healthcare Stocks: Bluebird Bio (BLUE), Immunic (IMUX)
The Top Five Long Crowded Stocks in Each U.S. Sector
Immunic Shares Are Trading Higher After the Company Announced the Presentation of Data at the ECTRIMS 40th Congress, Highlighting Its Lead Asset, Nuclear Receptor Related 1 Activator, Vidofludimus Calcium's Therapeutic Potential in Multiple Sclerosis.
Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis